JMP Securities lowered the firm’s price target on Hookipa Pharma to $23 from $50 and keeps an Outperform rating on the shares. Hookipa recently announced a major management change in conjunction with a strategic review intended to enhance the company’s focus on bringing HB-200 to market, which could involve refocusing efforts on different aspects of the business, with no timelines for completion, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOOK:
- HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
- Hookipa Pharma appoints Peters as CEO, Coelho as EVP, CFO
- HOOKIPA Pharma trading halted, news pending
- Upcoming Stock Splits This Week (July 8 to July 12)
- JMP Securities healthcare analysts hold an analyst/industry conference call